CRDL$1.06
Chart
Performance
Key Stats
AI CRDL Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldCardiol Therapeutics Inc. operates in a high-demand therapeutic area with a promising pipeline, but faces near-term revenue generation challenges and needs to demonstrate clinical efficacy. Its valuation is currently below traditional metrics due to its clinical-stage nature. Investors should monitor clinical trial progress and regulatory approvals.
Thematic
Cardiol Therapeutics is focused on a significant unmet need in cardiovascular diseases, particularly in areas like myocarditis and pericarditis. The growing prevalence of heart disease globally and advancements in targeted therapies create a positive thematic backdrop.
Fundamental
As a clinical-stage company, Cardiol Therapeutics currently has no revenue and is operating at a loss, typical for its stage. Its financial strength relies heavily on its cash reserves to fund ongoing research and development. Dilution from potential future financings is a consideration.
Technical
The stock has experienced significant volatility. While it has shown some recent positive momentum and is trading above key long-term moving averages, it also exhibits signs of being overbought on shorter timeframes, suggesting potential for consolidation or a short-term dip.
| Factor | Score |
|---|---|
| Cardiovascular Disease Market | 85 |
| Anti-fibrotic & Anti-inflammatory Therapies | 80 |
| Clinical Trial Success Probability | 70 |
| Drug Development Landscape | 75 |
| Healthcare Innovation | 80 |
| Factor | Score |
|---|---|
| Valuation | 10 |
| Profitability | 5 |
| Growth | 5 |
| Balance Sheet Health | 70 |
| Cash Flow | 15 |
| Factor | Score |
|---|---|
| Trend Analysis | 75 |
| Momentum | 50 |
| Volume Confirmation | 40 |
| Support & Resistance | 50 |
| Short-Term Oscillators | 40 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Focus on Promising Therapies
Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing anti-fibrotic and anti-inflammatory therapies for heart diseases. Its lead product candidate, CardiolRx, is in Phase III trials for acute myocarditis and recurrent pericarditis, indicating a strong pipeline.
Recent Positive Performance
The stock has shown positive short-term performance, with a 5-day return of 2.86% and a 1-month return of 2.13%. The 6-month return of 11.63% suggests upward momentum.
Bearish Points (7)
No Revenue and Negative Earnings
The company has reported zero total revenue for the periods ending 2021Q4 through 2024Q4. Earnings per share (EPS) are consistently negative, with an EPS-TTM of -0.35. This reflects the early-stage, pre-revenue nature of the business.
High Market Capitalization Relative to Stage
Despite zero revenue, the market capitalization is approximately $119 million. This valuation is based solely on future potential and carries significant risk if clinical trials do not yield positive results or if the drug does not achieve market approval.
Calendar
August 2025
13
Next Earnings Date
H: $-0.12
A: $-0.12
L: $-0.12
Profile
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
Seasonals
Price Target
8.92 USD
The 39 analysts offering 1 year price forecasts for CRDL have a max estimate of 10.13 and a min estimate of 7.99.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Leading pure-play operator of behavioral healthcare facilities, directly comparable in industry focus and potential acquisition strategy for a holding company like CRDL.
Weight: 96
Largest outpatient mental health and a significant employer of psychiatrists, psychologists, and therapists; a direct peer in the behavioral health service delivery space.
Weight: 95
Major provider of hospital and healthcare services, with a significant behavioral health division that operates freestanding psychiatric facilities and behavioral health units.
Weight: 92
A diversified healthcare enterprise with a substantial presence in behavioral health through its acquisition of Magellan Health, providing managed care solutions.